TCHB.F Stock Overview
Provides laboratory instruments and solutions for pharmaceutical, biotechnology and in-vitro diagnostic companies, university research departments, and diagnostic and other laboratories. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Tecan Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 277.00 |
| 52 Week High | CHF 400.00 |
| 52 Week Low | CHF 277.00 |
| Beta | 0.70 |
| 11 Month Change | 0% |
| 3 Month Change | -18.59% |
| 1 Year Change | n/a |
| 33 Year Change | -55.85% |
| 5 Year Change | 23.82% |
| Change since IPO | 815.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| TCHB.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 5.3% | 2.2% |
| 1Y | n/a | 4.8% | 32.6% |
Return vs Industry: Insufficient data to determine how TCHB.F performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how TCHB.F performed against the US Market.
Price Volatility
| TCHB.F volatility | |
|---|---|
| TCHB.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TCHB.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine TCHB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 3,000 | Achim von Leoprechting | www.tecan.com |
Tecan Group AG provides laboratory instruments and solutions for pharmaceutical, biotechnology and in-vitro diagnostic companies, university research departments, and diagnostic and other laboratories. It operates through Life Sciences Business and Partnering Business segments. The company offers liquid handling and automation, microplate readers and washers, consumables, NGS reagents, immunoassays and antibodies, and software; and Tecan Labwerx, an automation solution.
Tecan Group AG Fundamentals Summary
| TCHB.F fundamental statistics | |
|---|---|
| Market cap | US$3.02b |
| Earnings (TTM) | US$113.81m |
| Revenue (TTM) | US$1.12b |
26.6x
P/E Ratio2.7x
P/S RatioIs TCHB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCHB.F income statement (TTM) | |
|---|---|
| Revenue | CHF 1.00b |
| Cost of Revenue | CHF 653.34m |
| Gross Profit | CHF 346.71m |
| Other Expenses | CHF 245.37m |
| Earnings | CHF 101.34m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 12, 2025
| Earnings per share (EPS) | 7.90 |
| Gross Margin | 34.67% |
| Net Profit Margin | 10.13% |
| Debt/Equity Ratio | 17.8% |
How did TCHB.F perform over the long term?
See historical performance and comparison